FDMT Earnings & Financial Statements
4D Molecular Therapeutics, Inc.
$12.20
-$0.16(-1.29%)
44
Overall
60
Value
30
Tech
44
Quality
Market Cap
$673.98M
Volume
632.96K
52W Range
$6.96 - $16.93
Target Price
$28.55
FDMT earnings and financial statements: 4D Molecular Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
FDMT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $85.21M | $37.0K | $20.72M | $3.13M | $18.04M |
| Operating income | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M |
| EBITDA | -$132.48M | -$154.16M | -$95.09M | -$106.15M | -$68.31M |
| Net income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M |
| EPS (diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $566.71M | $560.38M | $339.89M | $261.85M | $353.49M |
| Total liabilities | $61.05M | $49.78M | $32.06M | $30.51M | $34.38M |
| Shareholders’ equity | $505.66M | $510.61M | $307.83M | $231.34M | $319.11M |
| Cash and equivalents | $60.24M | $149.34M | $249.11M | $52.35M | $153.00M |
| Long-term debt | $15.82M | $18.97M | $11.52M | $13.47M | $15.22M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$109.08M | -$134.59M | -$75.79M | -$86.69M | -$69.13M |
| Capital expenditure | -$536.0K | -$3.79M | -$2.77M | -$11.54M | -$9.11M |
| Free cash flow | -$109.62M | -$138.37M | -$78.56M | -$98.22M | -$78.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FDMT | $12.20 | -1.3% | 632.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get 4D Molecular Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW